News

  • Mar 13, 2017

    Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France (Read more)

  • Dec 6, 2016

    Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea (Read more)

  • Nov 16, 2016

    Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Australia and New Zealand (Read more)

  • Nov 2, 2016

    Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (“PedPRM”) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD) (Read more)

  • Oct 5, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Honduras

  • Sep 28, 2016

    Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION – phase II clinical trial of Piromelatine for mild Alzheimer’s disease (Read more)

  • Aug 2, 2016

    Circadin® receives marketing authorization in Honduras

  • Jun 21, 2016

    Circadin® is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders (Read more)

  • Mar 3, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Peru

  • Mar 2, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

  • Jan 11, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in South Africa

  • Oct 1, 2015

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Colombia

  • Sep 18, 2015

    Circadin® receives marketing authorization in Peru

  • Mar 2, 2015

    Vigisom® 2mg (prolonged-release melatonin) is now commercially available in Chile

  • Sep 7, 2014

    Circadin® receives marketing authorization in South Africa

  • Sep 1, 2014

    Circadin® receives marketing authorization in South Korea

  • Aug 27, 2014

    Neurim Pharmaceuticals initiates Phase III study of Paediatric Prolonged-Release Melatonin in children with Autistic Spectrum Disorders, suffering from sleep disturbances

  • Jun 19, 2014

    Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer’s Disease Patients (Read more)

  • Feb 18, 2013

    Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia (Read more)

  • Feb 22, 2012

    Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France
    • Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea
    • Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Australia and New Zealand
  • Partners

    Partners